diabetes

These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema.

Researchers showed that insulin resistance exists on a spectrum among diabetics and healthy controls. 

Explore the link between GLP-1 drugs and cancer. A new study reveals these therapies may reduce the risk of obesity-related cancers, similar to bariatric surgery.

To help clinicians monitor slow-healing chronic wounds, researchers created the iCares device and tested it in 20 people with a variety of wounds.

Two new FDA approvals and promising clinical trial results for drugs to treat diabetes and lung cancer, and more led the news this week.

Plummeting blood sugar can accelerate eye damage due to diabetes. Results in mice suggest that a new drug targeting hypoxia inducible factor could help.

Placental extracellular vesicles from maternal blood plasma identified women who would go on to develop complications later in their pregnancy.

GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.

Targeting a gut bacterial species or its metabolites could potentially improve diabetes management by reducing sugar preferences.